Latest Conference Articles

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, explains that later cytopenias should be monitored in patients undergoing CAR T-cell therapy.

Durvalumab plus FLOT chemotherapy improved overall survival in resectable gastric or gastroesophageal junction cancer, per phase 3 MATTERHORN data.

An oncology APP-led quality assurance committee identified key safety events across disciplines and specialties.

The frontline addition of cancer vaccine IO102-IO103 to pembrolizumab demonstrated an increase in PFS in patients with advanced melanoma.

Daniel Glidden, MS, PA-C, discusses key data oncology APPs should be aware of and how to start incorporating exercise in cancer care.

T-DXd plus pertuzumab improved PFS and DOR across HER2+ breast cancer subgroups, regardless of prior therapy or PIK3CA mutation status.

Disitamab vedotin/toripalimab improved PFS and OS vs chemotherapy in HER2-expressing advanced urothelial carcinoma, per phase 3 RC48-C016 data.

Treatment for patients with R/R multiple myeloma should be based on the individual patient and their history, said Lisa Hwa Christenson, DNP, APRN, CNP.

Among lymphoma survivors, a multidisciplinary intervention program had a beneficial effect on fatigue and aspects of health-related quality of life.

Using gender-neutral language is the first step in making a safe space for LGBTQIA+ patients with cancer, explained Al Asante-Facey, PA, MBA.

Supervised physical activity, while feasible, was not shown to affect quality of life or fatigue in patients with metastatic cancer.

Paola Gonzalez, MPAS, PA-C, explains how third-party vendors shape insurance guidelines and what oncology APPs should know when navigating peer-to-peer reviews.

Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.

Adding platinum-based chemotherapy to osimertinib improved overall survival vs osimertinib alone in EGFR-mutated NSCLC, even in high-risk subgroups.

Sevabertinib demonstrated robust, durable responses and manageable safety in both treatment-naive and pretreated patients with HER2-mutant advanced NSCLC.

A patient with breast cancer and generalized anxiety disorder was able to avoid an unnecessary mastectomy with virtual reality, said Kelly Preti, DNP.

A multisite advanced practice optimization model improved patient access through tailored interventions, including redistributing non-APP responsibilities.

Frontline lenvatinib, pembrolizumab, and chemotherapy did not lead to increased overall survival vs chemoimmunotherapy in patients with advanced ESCC.

T-DXd plus pertuzumab improved progression-free survival vs THP regardless of prior therapy, hormone receptor status, or PIK3CA mutations.

The combination of sacituzumab with pembrolizumab did not lead to a decline in physical functioning or quality of life in patients with metastatic TNBC.

Buparlisib combined with paclitaxel failed to improve overall survival vs paclitaxel alone for patients with PD-1/PD-L1–pretreated HNSCC.

Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases to become chronic.

Adding zabilugene almadenorepvec to SOC chemotherapy and nab-paclitaxel was safe and effective in patients with metastatic pancreatic ductal adenocarcinoma.

Ivonescimab plus chemotherapy improved progression-free survival and response rates with manageable safety vs tislelizumab in advanced squamous NSCLC.

The DESTINY-Breast11 trial found neoadjuvant T-DXd followed by THP improved pathologic complete response vs ddAC-THP in high-risk, HER2-positive early breast cancer.

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor (AI) improves invasive disease–free survival vs AI alone in HR+, HER2– early breast cancer.

Adding perioperative durvalumab to neoadjuvant chemotherapy did not worsen health-related quality of life for patients with muscle-invasive bladder cancer.